Bioplus Acquisition Corp Stock Beta
BioPlus Acquisition Corp fundamentals help investors to digest information that contributes to BioPlus Acquisition's financial success or failures. It also enables traders to predict the movement of BioPlus Stock. The fundamental analysis module provides a way to measure BioPlus Acquisition's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioPlus Acquisition stock.
BioPlus |
BioPlus Acquisition Corp Company Beta Analysis
BioPlus Acquisition's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current BioPlus Acquisition Beta | 0.14 |
Most of BioPlus Acquisition's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioPlus Acquisition Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, BioPlus Acquisition Corp has a Beta of 0.14. This is 82.93% lower than that of the Capital Markets sector and significantly higher than that of the Financials industry. The beta for all United States stocks is 193.33% lower than that of the firm.
BioPlus Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioPlus Acquisition's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioPlus Acquisition could also be used in its relative valuation, which is a method of valuing BioPlus Acquisition by comparing valuation metrics of similar companies.BioPlus Acquisition is currently under evaluation in beta category among its peers.
As returns on the market increase, BioPlus Acquisition's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioPlus Acquisition is expected to be smaller as well.
BioPlus Fundamentals
| Return On Asset | -0.0072 | |||
| Current Valuation | 215.16 M | |||
| Shares Outstanding | 19.37 M | |||
| Shares Owned By Insiders | 48.69 % | |||
| Shares Owned By Institutions | 51.31 % | |||
| Number Of Shares Shorted | 1.64 K | |||
| Price To Earning | (3.62) X | |||
| EBITDA | (1.17 M) | |||
| Net Income | 2 M | |||
| Cash And Equivalents | 294.69 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 5 M | |||
| Debt To Equity | 7.23 % | |||
| Current Ratio | 2.96 X | |||
| Book Value Per Share | (0.86) X | |||
| Cash Flow From Operations | (691.47 K) | |||
| Short Ratio | 0.03 X | |||
| Earnings Per Share | 0.21 X | |||
| Price To Earnings To Growth | (7.93) X | |||
| Target Price | 20.0 | |||
| Number Of Employees | 38 | |||
| Beta | 0.14 | |||
| Market Capitalization | 208.98 M | |||
| Total Asset | 238.32 M | |||
| Retained Earnings | (14.78 M) | |||
| Working Capital | 21.89 K | |||
| Current Asset | 183.69 M | |||
| Current Liabilities | 152.76 M | |||
| Z Score | 24.97 | |||
| Net Asset | 238.32 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in BioPlus Stock
If you are still planning to invest in BioPlus Acquisition Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioPlus Acquisition's history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |